(Q37242489)

19 August 2017

title

Prisons and HCV: a review and a report on an experience in New South Wales Australia (English)

1 reference

19 August 2017

0 references

R G Batey

1

1 reference

19 August 2017

T Jones

series ordinal

2

1 reference

19 August 2017

C McAllister

series ordinal

3

1 reference

19 August 2017

publication date

1 January 2008

1 reference

International Journal of Prisoner Health

19 August 2017

published in

1 reference

19 August 2017

volume

4

1 reference

19 August 2017

issue

3

1 reference

19 August 2017

page(s)

156-163

1 reference

Treatment of chronic hepatitis C in a state correctional facility

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Mental health status of Aboriginal and non-Aboriginal Australian prisoners.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Treatment of chronic hepatitis C in Canadian prison inmates

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Feasibility and Outcome of HCV Treatment in a Canadian Federal Prison Population

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Past, present, and future hepatitis C treatments

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Risk factors for hepatitis C infection and perception of antibody status among male prison inmates in the Hepatitis C Incidence and Transmission in Prisons Study cohort, Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Hepatitis C virus reinfection in injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

The prevalence and the risk behaviours associated with the transmission of hepatitis C virus in Australian correctional facilities

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Peginterferon and ribavirin for chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Modeling the current and future disease burden of hepatitis C among injection drug users in Scotland

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Treatment of acute hepatitis C with interferon alfa-2b

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Reconsidering the public health failings of the criminal justice system: a reflection on the case of Scott Ortiz

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Substance use and treatment seeking in young offenders on community orders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Descriptive epidemiology of hepatitis C virus among male heroin abusers in Taiwan

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Incidence and risk factors for hepatitis C seroconversion in injecting drug users in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Cost-efficacy analysis of peginterferon alfa-2b plus ribavirin compared with peginterferon alfa-2a plus ribavirin for the treatment of chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Acute hepatitis C virus infection in incarcerated injection drug users

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Clearance of hepatitis C viremia associated with cellular immunity in the absence of seroconversion in the hepatitis C incidence and transmission in prisons study cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Intellectual disability and mental illness in the NSW criminal justice system.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Hepatitis C treatment in "difficult-to-treat" psychiatric patients with pegylated interferon-alpha and ribavirin: response and psychiatric side effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Evaluation of a prison outreach clinic for the diagnosis and prevention of hepatitis C: implications for the national strategy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

A framework for management of hepatitis C in prisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Modelling the force of infection for hepatitis B and hepatitis C in injecting drug users in England and Wales

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Estimating the cost-effectiveness of detecting cases of chronic hepatitis C infection on reception into prison

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

The effect of hepatitis C virus infection on health-related quality of life in prisoners

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Hepatitis C: cost of illness and considerations for the economic evaluation of antiviral therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

Hepatitis infection among adolescents resident in Melbourne Juvenile Justice Centre: risk factors and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F17449200802264712

10.1080/17449200802264712

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference